Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins
NCT ID: NCT01271881
Last Updated: 2011-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
140 participants
INTERVENTIONAL
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed to compare angioplasty (standard of care) versus using a covered stent graft. The investigators will then look at the dialysis records and future fistulograms to see if there is decreased flow through the fistula at 3, 6 and 12 months after the initial procedure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries
NCT05143138
GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
NCT00228384
A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
NCT02080871
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
NCT05811364
GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study
NCT04429243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Percutaneous Transluminal Angioplasty (PTA) alone
Intervention: Procedure: PTA alone without use of the GORE VIABAHN
PTA alone without use of the GORE VIABAHN
PTA alone with no stent used
PTA with covered stent
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Covered stent produced by GORE VIABAHN
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PTA alone without use of the GORE VIABAHN
PTA alone with no stent used
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Covered stent produced by GORE VIABAHN
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient is ≥ 18 years of age.
3. The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
4. The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.
5. The patient or his/her legal guardian is willing to provide informed consent.
Exclusion Criteria
2. The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.
3. The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (\>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.
4. The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
5. The patient has known sensitivity to heparin.
6. The patient is scheduled for a live donor kidney transplant.
7. The patient is enrolled in another investigational study or another access maintenance trial
8. The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements
9. Life expectancy is ≤ 24 months.
10. The patient has an untreatable allergy to radiographic contrast material.
11. The patient is pregnant.
12. In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.
13. The patient's access is planned to be abandoned within 1 year.
14. The patient has indwelling catheters (dialysis, pacemakers, ports).
15. The patient has a central vein stent that would lead to jailing of the internal jugular vein.
16. The patient experiences angioplasty-induced venous rupture.
17. The patient has a flow limiting dissection after angioplasty.
18. The patient's hemodialysis access is thrombosed.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Access Care
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
American Acess Care
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abigail Falk, Dr.
Role: PRINCIPAL_INVESTIGATOR
American Access Care Physician
Claudio Cantu, RPA
Role: STUDY_CHAIR
American Access Care Center Operations Manager
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
American Access Care of Queens
Flushing, New York, United States
American Access Care of Bronx
The Bronx, New York, United States
Access Care Physicians of New York
White Plains, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kiran Jotwani, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 1999 Nov-Dec;10(10):1405-15. doi: 10.1016/s1051-0443(99)70252-6. No abstract available.
Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, Miller A, Scher L, Trerotola S, Gregory RT, Rutherford RB, Kent KC. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg. 2002 Mar;35(3):603-10. doi: 10.1067/mva.2002.122025.
Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, Huang CC, Hsu TS, Lee YS, Pang JH. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis. 2004 Jan;43(1):74-84. doi: 10.1053/j.ajkd.2003.09.015.
Patel RI, Peck SH, Cooper SG, Epstein DM, Sofocleous CT, Schur I, Falk A. Patency of Wallstents placed across the venous anastomosis of hemodialysis grafts after percutaneous recanalization. Radiology. 1998 Nov;209(2):365-70. doi: 10.1148/radiology.209.2.9807560.
Rajan DK, Clark TW. Patency of Wallstents placed at the venous anastomosis of dialysis grafts for salvage of angioplasty-induced rupture. Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):242-5. doi: 10.1007/s00270-003-2706-x.
Haage P, Vorwerk D, Piroth W, Schuermann K, Guenther RW. Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Radiology. 1999 Jul;212(1):175-80. doi: 10.1148/radiology.212.1.r99jl21175.
Vogel PM, Parise C. SMART stent for salvage of hemodialysis access grafts. J Vasc Interv Radiol. 2004 Oct;15(10):1051-60. doi: 10.1097/01.RVI.0000129915.48500.DC.
Rajan DK, Saluja JS. Use of nitinol stents following recanalization of central venous occlusions in hemodialysis patients. Cardiovasc Intervent Radiol. 2007 Jul-Aug;30(4):662-7. doi: 10.1007/s00270-007-9083-9.
Chan MR, Bedi S, Sanchez RJ, Young HN, Becker YT, Kellerman PS, Yevzlin AS. Stent placement versus angioplasty improves patency of arteriovenous grafts and blood flow of arteriovenous fistulae. Clin J Am Soc Nephrol. 2008 May;3(3):699-705. doi: 10.2215/CJN.04831107. Epub 2008 Feb 6.
Pan HB, Liang HL, Lin YH, Chung HM, Wu TH, Chen CY, Fang HC, Chen CK, Lai PH, Yang CF. Metallic stent placement for treating peripheral outflow lesions in native arteriovenous fistula hemodialysis patients after insufficient balloon dilatation. AJR Am J Roentgenol. 2005 Feb;184(2):403-9. doi: 10.2214/ajr.184.2.01840403.
Shemesh D, Goldin I, Zaghal I, Berlowitz D, Raveh D, Olsha O. Angioplasty with stent graft versus bare stent for recurrent cephalic arch stenosis in autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. J Vasc Surg. 2008 Dec;48(6):1524-31, 1531.e1-2. doi: 10.1016/j.jvs.2008.07.071. Epub 2008 Oct 1.
Naoum JJ, Irwin C, Hunter GC. The use of covered nitinol stents to salvage dialysis grafts after multiple failures. Vasc Endovascular Surg. 2006 Aug-Sep;40(4):275-9. doi: 10.1177/1538574406291803.
Gupta M, Rajan DK, Tan KT, Sniderman KW, Simons ME. Use of expanded polytetrafluoroethylene-covered nitinol stents for the salvage of dysfunctional autogenous hemodialysis fistulas. J Vasc Interv Radiol. 2008 Jun;19(6):950-4. doi: 10.1016/j.jvir.2008.03.016. Epub 2008 Apr 28.
Clark TW, Rajan DK. Treating intractable venous stenosis: present and future therapy. Semin Dial. 2004 Jan-Feb;17(1):4-8. doi: 10.1111/j.1525-139x.2004.17103.x.
Yuan JG, Ohki T, Marin ML, Quintos RT, Krohn DL, Beitler JJ, Veith FJ. The effect of nonporous PTFE-covered stents on intimal hyperplasia following balloon arterial injury in minipigs. J Endovasc Surg. 1998 Nov;5(4):349-58. doi: 10.1583/1074-6218(1998)0052.0.CO;2.
Fontaine AB, Dos Passos S, Spigos D, Cearlock J, Urbaneja A. Use of polyetherurethane to improve the biocompatibility of vascular stents. J Endovasc Surg. 1995 Aug;2(3):255-65. doi: 10.1583/1074-6218(1995)0022.0.CO;2.
Related Links
Access external resources that provide additional context or updates about the study.
Kidney Failure
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GORE-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.